InsiderTrades.com logo
Most People Are Dead Wrong.
From Brownstone Research   |   Ad
Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.
I call it my AI Retirement Playbook. I recommend you check it out now.
Catriona Yale net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Catriona Yale Biography and Net Worth

Insider of Akero Therapeutics
Kitty Yale is Chief Development Officer of Akero Therapeutics. Kitty joins Akero from Gilead Sciences, where she led global clinical operations and management of the company’s oncology, HIV, inflammation, and liver disease trials, and held senior clinical research and operations roles at Gilead and Roche Global Development. As VP of Clinical Operations at Gilead, her most recent role prior to joining Akero, Kitty led global development programs resulting in eight drug approvals in the US, EMEA, Canada, Korea, Japan, and China.

What is Catriona Yale's net worth?

The estimated net worth of Catriona Yale is at least $2.81 million as of December 16th, 2024. Ms. Yale owns 95,648 shares of Akero Therapeutics stock worth more than $2,806,312 as of December 21st. This net worth evaluation does not reflect any other investments that Ms. Yale may own. Additionally, Ms. Yale receives an annual salary of $678,060.00 as Insider at Akero Therapeutics. Learn More about Catriona Yale's net worth.

How old is Catriona Yale?

Ms. Yale is currently 52 years old. There are 7 older executives and no younger executives at Akero Therapeutics. The oldest executive at Akero Therapeutics is Dr. Timothy Rolph, Co-Founder & Chief Scientific Officer, who is 70 years old. Learn More on Catriona Yale's age.

What is Catriona Yale's salary?

As the Insider of Akero Therapeutics, Inc., Ms. Yale earns $678,060.00 per year. There are 2 executives that earn more than Ms. Yale. The highest earning executive at Akero Therapeutics is Dr. Andrew Cheng M.D., Ph.D., President, CEO & Director, who commands a salary of $1,040,000.00 per year. Learn More on Catriona Yale's salary.

How do I contact Catriona Yale?

The corporate mailing address for Ms. Yale and other Akero Therapeutics executives is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. Akero Therapeutics can also be reached via phone at (650) 487-6488 and via email at [email protected]. Learn More on Catriona Yale's contact information.

Has Catriona Yale been buying or selling shares of Akero Therapeutics?

Over the course of the past ninety days, Catriona Yale has sold $1,351,663.40 in Akero Therapeutics stock. Most recently, Catriona Yale sold 9,074 shares of the business's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $29.11, for a transaction totalling $264,144.14. Following the completion of the sale, the insider now directly owns 95,648 shares of the company's stock, valued at $2,784,313.28. Learn More on Catriona Yale's trading history.

Who are Akero Therapeutics' active insiders?

Akero Therapeutics' insider roster includes Kevin Bitterman (Director), Andrew Cheng (CEO), William White (CFO), Catriona Yale (Insider), and Jonathan Young (COO). Learn More on Akero Therapeutics' active insiders.

Are insiders buying or selling shares of Akero Therapeutics?

During the last twelve months, insiders at the sold shares 44 times. They sold a total of 818,039 shares worth more than $24,252,058.49. The most recent insider tranaction occured on December, 16th when VP Patrick Lamy sold 1,000 shares worth more than $29,130.00. Insiders at Akero Therapeutics own 7.9% of the company. Learn More about insider trades at Akero Therapeutics.

Information on this page was last updated on 12/16/2024.

Catriona Yale Insider Trading History at Akero Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/16/2024Sell9,074$29.11$264,144.1495,648View SEC Filing Icon  
11/15/2024Sell9,061$27.73$251,261.5374,158View SEC Filing Icon  
11/1/2024Sell15,485$32.62$505,120.7074,158View SEC Filing Icon  
10/30/2024Sell4,515$32.53$146,872.9574,158View SEC Filing Icon  
10/14/2024Sell6,136$30.03$184,264.0874,158View SEC Filing Icon  
9/20/2024Sell5,500$27.65$152,075.0075,294View SEC Filing Icon  
9/18/2024Sell3,871$27.56$106,684.7675,294View SEC Filing Icon  
9/16/2024Sell2,485$27.52$68,387.2075,294View SEC Filing Icon  
9/10/2024Sell637$26.18$16,676.6675,294View SEC Filing Icon  
8/26/2024Sell5,200$27.51$143,052.0075,931View SEC Filing Icon  
8/23/2024Sell8,851$27.53$243,668.0375,931View SEC Filing Icon  
6/11/2024Sell2,825$22.64$63,958.0074,867View SEC Filing Icon  
3/4/2024Sell20,646$35.49$732,726.5478,415View SEC Filing Icon  
12/14/2023Sell597$20.76$12,393.7277,910View SEC Filing Icon  
9/21/2023Sell5,000$48.07$240,350.0046,010View SEC Filing Icon  
9/13/2023Sell617$50.34$31,059.7846,010View SEC Filing Icon  
8/28/2023Sell5,745$49.99$287,192.5546,627View SEC Filing Icon  
6/23/2023Sell11,000$50.76$558,360.0046,627View SEC Filing Icon  
6/21/2023Sell11,349$52.26$593,098.7468,627View SEC Filing Icon  
1/13/2023Sell5,000$50.53$252,650.0081,268View SEC Filing Icon  
12/12/2022Sell5,000$43.23$216,150.0086,268View SEC Filing Icon  
11/10/2022Sell5,000$39.42$197,100.0072,073View SEC Filing Icon  
10/10/2022Sell5,000$37.99$189,950.0077,073View SEC Filing Icon  
9/13/2022Sell40,000$27.48$1,099,200.0082,073View SEC Filing Icon  
10/15/2021Sell12,500$21.59$269,875.00View SEC Filing Icon  
8/16/2021Sell10,000$18.79$187,900.00145,921View SEC Filing Icon  
7/15/2021Sell10,000$20.90$209,000.00View SEC Filing Icon  
See Full Table

Catriona Yale Buying and Selling Activity at Akero Therapeutics

This chart shows Catriona Yale's buying and selling at Akero Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Akero Therapeutics Company Overview

Akero Therapeutics logo
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $29.34
Low: $28.09
High: $29.77

50 Day Range

MA: $30.89
Low: $28.09
High: $35.28

2 Week Range

Now: $29.34
Low: $15.32
High: $37.00

Volume

1,559,947 shs

Average Volume

844,736 shs

Market Capitalization

$2.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Most People Are Dead Wrong.
From Brownstone Research   |   Ad
Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.
I call it my AI Retirement Playbook. I recommend you check it out now.